Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.

Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.

The group has approval for Amtagvi, but now faces the prospect of a solo launch.

GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.

Lifileucel heads up the list of upcoming US FDA catalysts.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.

Private company trial initiations stand out in the latest week’s disclosures.

For now, the group is sticking with what it knows ahead of a big year in lymphoma.

A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.

Despite magrolimab’s latest flop, efforts to target CD47 continue.